comparemela.com
Home
Live Updates
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute - Phio Pharma (NASDAQ:PHIO) : comparemela.com
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute - Phio Pharma (NASDAQ:PHIO)
MARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make
Related Keywords
Oregon ,
United States ,
Bridge View ,
Portland ,
Robertw Franz ,
Michael Adams ,
Judith Ann Hartmann ,
Caitlin Kontulis ,
Andrew Weinberg ,
Brendan Curti ,
Robert Bitterman ,
Providence Cancer Institute Of Oregon ,
Phio Pharmaceuticals ,
Phio Pharmaceuticals Corp ,
Clinical Research ,
Laboratory Of Basic Immunology ,
Joseph Health ,
Providence Cancer Institute In Portland ,
Agonox Inc ,
Earlea Chiles Research Institute ,
Providence Cancer Institute ,
Adoptive Cell Therapy ,
Principal Investigator Brendan Curti ,
Endowed Chair ,
Research Institute ,
Judith Ann Hartmann Endowed Chair ,
Basic Immunology ,
Cancer Institute ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Reports ,
comparemela.com © 2020. All Rights Reserved.